Physiomics Regulatory News (PYC)

8 July 2026

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded Multiple New Contracts

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has secured multiple contract awards with a combined estimated value in excess of £200,000.

The awards comprise a combination of follow-on engagements within the Company's Biometrics service line and a new contract within its Modelling & Simulation business. The Biometrics awards include two extensions to existing clinical development engagements: one with a clinical-stage biotechnology company focused on immunology and one with a clinical-stage biotechnology company focused on infectious disease.

In addition, the Company has secured a new Modelling & Simulation contract with a Boston-based biotechnology company developing novel immunotherapies for cancer.

The projects will utilise the Company's expertise across biostatistics, modelling and simulation to support key stages of drug development, including data analysis, development programme support and model-informed development. The Board believes these awards further demonstrate the continued development of Physiomics' diversified service offering, the strength of its client relationships and its ability to support increasingly complex projects across both existing and new clients.

Jesse Thissen, Chief Operating Officer of Physiomics, commented: "We are pleased to have secured these awards, which reflect the continued progress of our Biometrics service line alongside our established Modelling & Simulation capabilities. Since opening our Biometrics department, we have focused on building the processes and technical infrastructure required to support more complex client engagements for both Biometrics and MIDD. The mix of follow-on and new work across Biometrics and Modelling & Simulation demonstrates the increasing breadth of our offering and our ability to provide quantitative support to biotech clients across multiple stages of development."

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.